Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 November 2003, Vol. 102, No. 10, pp. 3753-3758.
Prepublished online as a Blood First Edition Paper on July 24, 2003; DOI 10.1182/blood-2003-02-0626.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-02-0626v1
102/10/3753    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boudová, L.
Right arrow Articles by Rüdiger, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boudová, L.
Right arrow Articles by Rüdiger, T.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma

Ludmila Boudová, Emina Torlakovic, Jan Delabie, Peter Reimer, Beate Pfistner, Sabine Wiedenmann, Volker Diehl, Hans-Konrad Müller-Hermelink, and Thomas Rüdiger

From the Department of Pathology, Charles University, Pilsen, Czech Republic; Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway; Medizinische Poliklinik, University of Würzburg, Germany; German Hodgkin Lymphoma Study, Cologne, Germany; and the Department of Pathology, University of Würzburg, Germany.

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and T-cell/histiocyte-rich B-cell lymphoma (T/HRBCL) are distinct tumors and are treated differently. They are linked by a morphologic and probably a biologic continuum, which renders the differential diagnosis difficult. To develop criteria to distinguish the entities along the morphologic continuum, we correlated the lymph node architecture and immunophenotype of both tumor cells and reactive components of 235 neoplasms in the spectrum of NLPHL and T/HRBCL with clinical data. Two hundred and eighteen cases fitted the World Health Organization (WHO) criteria of NLPHL (139) or T/HRBCL (79). While tumor cells in both entities were immunophenotypically similar, background composition differed: in NLPHL small B cells and CD3+CD4+CD57+ T cells were common, whereas in T/HRBCL, CD8+ cytotoxic T cells and histiocytes dominated. Follicular dendritic cells (FDCs) formed expanded meshworks in NLPHL, whereas they were absent in T/HRBCL. Seventeen cases represented a gray zone: within FDC meshworks, neoplastic B cells resided in a background depleted of small B cells but rich in T cells and histiocytes. Tumor cells either were loosely scattered or formed clusters, thus resembling areas of either T/HRBCL or inflammatory diffuse large BCL (DLBCL) within the nodules. Patients with these NLPHLs with T-cell/histiocyte-rich nodules presented at a high stage and with B symptoms, as in T/HRBCL, but had an excellent survival, as in NLPHL. This morphologic pattern suggests a biologic continuum between NLPHL and T/HRBCL. (Blood. 2003;102:3753-3758)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JCOHome page
L. Nogova, T. Reineke, C. Brillant, M. Sieniawski, T. Rudiger, A. Josting, H. Bredenfeld, R. Skripnitchenko, R.-P. Muller, H.-K. Muller-Hermelink, et al.
Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
J. Clin. Oncol., January 20, 2008; 26(3): 434 - 439.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Schulz, U. Rehwald, F. Morschhauser, T. Elter, C. Driessen, T. Rudiger, P. Borchmann, R. Schnell, V. Diehl, A. Engert, et al.
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Blood, January 1, 2008; 111(1): 109 - 111.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. S. Abramson
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Oncologist, April 1, 2006; 11(4): 384 - 392.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
L. Nogova, T. Rudiger, and A. Engert
Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Hematology, January 1, 2006; 2006(1): 266 - 272.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Monti, K. J. Savage, J. L. Kutok, F. Feuerhake, P. Kurtin, M. Mihm, B. Wu, L. Pasqualucci, D. Neuberg, R. C. T. Aguiar, et al.
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
Blood, March 1, 2005; 105(5): 1851 - 1861.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020